The Effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Cancer

Volumn 113, Issue 6, 2008, Pages 1338-1343

  Aribi, Ahmed ^a   Kantarjian, Hagop ^a   Koller, Charles ^a   Thomas, Deborah ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; DASATINIB; DIURETIC AGENT; IMATINIB; INTERLEUKIN 11; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BLURRED VISION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-11; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PLATELET COUNT; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 53149104746     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23718     Document Type: Article

References (22)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
2. Hochhaus A, Druker B, Sawyers C, et al. Favorable longterm follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronicphase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008; 111:1039-1043.
3. Cortes J, Bruemmendorf T, Kantarjian H, et al. Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph + chronic myelogenous leukemia (CML) [abstract]. Blood. 2007;110. Abstract 733.
4. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309.
5. Kantarjian H, Cortes J, Le Coutre P, et al. A phase I study of INNO-406 in patients with advanced Philadelphia (Ph + chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [abstract]. Blood. 2007;110. Abstract 469.
6. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546.
7. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100:116-121.
8. Cortes I, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004;100:2396-2402.
9. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony- stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronicphase chronic myelogenous leukemia. Cancer. 2004;100: 2592-2597.
10. Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica. 2003;88:227-229.
11. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615-3624.
12. Saitoh M, Taguchi K, Momose K, Suga K, Yamazaki N, Ono C, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother Pharmacol. 2002;49:161-166.
13. Tepler I, Elias L, Smith JW 2nd, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607-3614.
14. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165-4172.
15. Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005;16:139-145.
16. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 may improve thrombocytopenia associated with imatinib mesylate therapy in chronic myelogenous leukemia. Leuk Res. 2004;28:613-618.
17. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
18. Musashi M, Yang YC, Paul SR, Clark SC, Sudo T, Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA. 1991;88: 765-769.
19. Turner KJ, Neben S, Weich N, Schaub RG, Goldman SJ. The role of recombinant interleukin 11 in megakaryocytopoiesis. Stem Cells. 1996;14(suppl 1):53-61.
20. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997;15:3368-3377.
21. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997;89:3897-3908.
22. Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. Oncology (Huntington). 2000;14(9 suppl 8):9-11.